NICE rejects “routine” use of cabazitaxel in UK

According to a media release issued today by the National Institute for Clinical Excellence (NICE) in the UK, the institute’s advisory board will not recommend “routine” use of cabazitaxel for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Cabazitaxel, abiraterone acetate: efficacy and safety in “real world” clinical practice

Early data from a German report seems to suggest that the clinical effects of cabazitaxel and abiraterone acetate in routine clinical practice are similar to those observed in Phase III clinical trials. … READ MORE …

OncoGeneX/Teva halt SATURN trial, start new Phase III study with OGX-011

According to a media release from the companies issued yesterday, OncoGeneX and Teva have stopped enrolling patients into the SATURN trial, which was designed to see if OGX-011 (custirsen) could ameliorate bone pain … READ MORE …

Tasquinimod + cabazitaxel in heavily pre-treated men with mCRPC

According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

NICE says “no” to cabazitaxel in the UK … at least for the moment

In the United Kingdom (UK), the National Institute for Health and Clinical Excellence (NICE) has issued initial (draft) guidance that recommends against coverage of the costs of second-line chemotherapy with cabazitaxel (Jevtana®) and prednisone (or prednisolone). … READ MORE …

Expert commentary on new drugs for mCRPC

A videotaped expert commentary by Dr. Johann de Bono on the Medscape Oncology web site (with transcript) discusses four therapies (three now approved in the USA) that have recently demonstrated a survival benefit in the treatment of metastatic, castration-resistant prostate cancer.

UK’s National Health Service will not pay for cabazitaxel in mCRPC (at the proposed price)

According to a report in today’s Daily Telegraph, the UK’s National Institute for Health and Clinical Excellence (NICE) has determined that “cabazitaxel would not be a cost effective use of limited NHS resources” for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Oncogenex makes SATURN trial of custirsen (OGX-011) more accessible

The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo. … READ MORE …

Wishful thinking about abiraterone acetate in CRPC

An article from Thursday’s “The Pink Sheet”, posted on the OncologySTAT web site today, is already asking questions about the potential future use of abiraterone acetate in patients with non-metastatic, castration-resistant prostate cancer (CRPC). … READ MORE …

Cabazitaxel gets final approval for marketing in Europe

According to a media release from Sanofi-Aventis, the European Commission has authorized marketing of cabazitaxel (Jevtana®) in all 27 countries of the European Union in combination with prednisone or prednisolone. … READ MORE …

European Medicines Agency approves cabazitaxel

According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana) … READ MORE …

Report provides final results of the TROPIC trial of cabazitaxel

Cabazitaxel (Jevtana®) has recently been approved in the USA for the treatment of men with castration-resistant prostate cancer who have progressive disease following treatment with standard first-line chemotherapy (docetaxel + prednisone). … READ MORE …

US FDA approves cabazitaxel for late-stage prostate cancer

Somewhat “out of the blue,” the US Food and Drug Administration (FDA), earlier today, approved Sanofi-Aventis’s “second-generation” taxane, cabazitaxel (Jevtana®) in combination with prednisone for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

How serious ARE the side effects of cabazitaxel?

As has been previously mentioned on this web site, cabazitaxel — a second-generation taxane — has a good chance of being approved some time soon for the treatment of patients with castration-resistant prostate cancer (CRPC) who have already progressed after treatment of docetaxel (Taxotere). However, … READ MORE …

Sunday at the ASCO annual meeting

There were a number of significant prostate cancer presentations today, and while none of them were “game changing” (for a variety of reasons), they are certainly worthy of notice. … READ MORE …